title: Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
abstract: Drug-eluting bioresorbable vascular scaffold (BVS) is a revolutionary treatment option for obstructive coronary artery disease in percutaneous coronary intervention. It restores blood flow to the myocardium but unlike permanent metallic stent, BVS dissolves in the body within 2 years. This allows the coronary vessel to regain its normal function and motion. The clinical efficacy and safety of BVS in the first-in-human trials have been reported with low major adverse cardiac event rates observed at short- and long-term follow-up. The incidence of BVS scaffold thrombosis (ST) in these studies was 0 %. There is limited data on the incidence of BVS ST in the real world. We report 2 cases of subacute ST involving BVS in our real-world practice and discuss on the possible mechanisms of these thrombotic episodes (with insights from intracoronary imaging studies).
authors.affiliation: Department of Cardiology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore, hokai_wah@yahoo.com.
authors.forename: Hee Hwa
authors.initials: HH
authors.lastname: Ho
authors.forename: Min
authors.initials: M
authors.lastname: Er Ching
authors.forename: Paul Jau Lueng
authors.initials: PJ
authors.lastname: Ong
authors.forename: Yau Wei
authors.initials: YW
authors.lastname: Ooi
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects*; D000241:Adenosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000628:therapy*; D003328:Coronary Thrombosis / Q000209:etiology*; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology*; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077144:Clopidogrel; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine; D001241:Aspirin
references.citation: JAMA. 2005 May 4;293(17):2126-30
references.pmid: 15870416
references.citation: Expert Rev Med Devices. 2012 Jul;9(4):327-38
references.pmid: 22420293
references.citation: Circulation. 2007 Feb 27;115(8):1051-8
references.pmid: 17325255
references.citation: Heart Vessels. 2012 Jan;27(1):106-9
references.pmid: 21445598
references.citation: JACC Cardiovasc Interv. 2013 Oct;6(10):999-1009
references.pmid: 24156961
references.citation: J Am Coll Cardiol. 2011 Oct 4;58(15):1578-88
references.pmid: 21958884
references.citation: Expert Rev Cardiovasc Ther. 2013 Oct;11(10):1407-16
references.pmid: 24138526
references.citation: Heart Vessels. 2012 Nov;27(6):634-8
references.pmid: 22218740
references.citation: Catheter Cardiovasc Interv. 2011 Jul 1;78(1):3-12
references.pmid: 21413120